Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Dachs1on Apr 12, 2016 10:01am
110 Views
Post# 24755966

RE:update from an german stock information letter

RE:update from an german stock information lettergoogle translator: our absolute top pick in the biotech sector is as before Sirona Biochem (WKN: A0RM6R). last days to die trended share something weak, had them die well opened last chance yourself die Sirona shares as low place to the depot. Solo's reported for the current quarter Mega-licensing deal for the new skin whitening provides a lot of upside potential. Yesterday Sirona Biochem announced the start of one research cooperation Dr. Caigan you by the University of British Columbia MIT. It is about to die investigate the efficacy of new drug compounds Sirona Biochem to application in the preservation of red blood cells (RBC) and other cells. The aim is to storability of blood products die Significantly increase. Results Will place for the fourth quarter 2016 expected. increases Analysts at First Berlin Equity Research HAVE recently also their price target for die Sirona Biochem share to 0.98 CAD, was around 0.67 euros and THEREFORE Einem profit potential of over 400 per cent Equivalent. And this could only be the beginning, because die analysts cave envisaged licensing deal with HER new target price not yet considered
Bullboard Posts